Objective. To develop a new chronic rheumatoid arthritis model that is driven by the innate immune system.
Methods. Injection of a cocktail of 4 monoclonal antibodies against type II collagen, followed on days 5 and 60 by intraperitoneal injections of mannan (from Saccharomyces cerevisiae), was used to induce development of chronic arthritis in B10.Q mice. The role of the innate immune system as compared to the adaptive immune system in this arthritis model was investigated using genetically modified mouse strains.
Results. A new model of chronic relapsing arthritis was characterized in B10.Q mice, in which a persistently active, chronic disease was found. This relapsing disease was driven by macrophages lacking the ability to mount a reactive oxygen species response against pathogens, and was associated with the classical/alternative pathway, but not the lectin pathway, of complement activation. The disease was independent of Fcc receptor type III, and also independent of the activity of adaptive immune cells (B and T cells), indicating that the innate immune system, involving complement activation, could be the sole driver of chronicity.
Conclusion. Chronic active arthritis can be driven innately by macrophages without the involvement of T and B cells in the adaptive immune system. Rheumatoid arthritis (RA) is a common autoimmune disease, present in~1% of the population. It causes joint pain and degradation, and, if left untreated, can lead to cardiovascular disease and other comorbidities that result in disability and decreased quality of life. RA is in part dependent on genetics; among the genes that are reported to contribute to the development of RA are the major histocompatibility complex (MHC) class II region, protein tyrosine phosphatase N22, and neutrophil cytosolic factor 1 (NCF-1) (1-3). NCF-1 has an essential role in the NADPH oxidase 2 (NOX-2) complex, which in turn has an important role in the defense against pathogens through the production of reactive oxygen species (ROS). Besides being important for the defense against infectious organisms, ROS are believed to modify signaling within and between cells. ROS could regulate inflammation by 1) acting as a synaptic transmitter, which down-regulates the interacting T cell (4, 5) , 2) increasing the pH in endosomes (6) thereby modifying peptide loading on the MHC (7), and 3) modifying intracellular signaling pathways by oxidizing protein thiols (8, 9) . It is thus probable that NOX-2-derived ROS affect autoimmune disease and inflammatory pathways in general, both via effects on pathways within the NOX-2-expressing macrophages and via effects on interacting cells such as Tcells.
Tcells, B cells, and macrophages play an important role in arthritis development (1) . A hallmark of RA is increased levels of autoantibodies, with antibodies against citrullinated peptides and antibodies against the Fc region of immunoglobulin molecules (called rheumatoid factors) appearing even before the onset of clinical features of the disease (1). However, it is still unclear whether the adaptive immune system drives the chronic relapsing disease after its initial clinical onset. The collagen antibody-induced arthritis (CAIA) model of acute arthritis was established using monoclonal antibodies directed against type II collagen (CII) (10) . It is a B and T cell-independent model of acute arthritis, and can be enhanced by injection of lipopolysaccharide (LPS) (11, 12) . Only a few other stimuli have been successfully shown to similarly enhance arthritis, including lipomannan (13) . However, CAIA resolves within a few weeks, and therefore there was a need to develop a new model of chronic arthritis. Existing models of chronic arthritis, such as collagen oligomeric matrix protein-induced arthritis, collagen-induced arthritis (CIA), proteoglycan-induced arthritis, and pristaneinduced arthritis (PIA), are all dependent on T cells, and the chronicity of disease in these models requires the activation of autoreactive T cells (10, (14) (15) (16) (17) (18) (19) (20) (21) . In each of these models, there is a long latent period prior to the development of arthritis, during which T and B cells are primed and differentiate into effector cells.
In the present report, we describe a novel chronic arthritis model that is independent of T and B cells. Our experiments identify macrophages and the complement cascade as the main drivers of chronic active disease in this model. The disease manifests clinically within days after its induction and, similar to RA, exhibits a relapsing disease course.
MATERIALS AND METHODS
Mice. The mice used in this study were backcrossed to a B10.Q background from B6; all were male and ages 8-20 weeks at the onset of the experiments. The experiments were performed either with littermates of the backcrossed mice or with non-littermates of mice that were fully backcrossed (>10 generations) and previously tested. All mice were age-matched and randomized to an experimental group, and the investigators were blinded with regard to the groups. Generation of the other mouse strains, , and C5 À/À mice, has been previously described (5, (22) (23) (24) . All mice were genotyped by polymerase chain reaction. B6.129P2-Fcgr3 tm1Sjv /J mice (acquired from The Jackson Laboratory) were backcrossed to B10Q.Ncf1 mice for at least 8 generations. The B6.129P2-Fcgr3 tm1Sjv /J mice were genotyped using the primers 5 0 -GTG-GCT-GAA-AAG-TTG-CTG-CTG-3 0 , 5 0 -CTA-CAT-CCT-CCA-TCT-CTC-TAG-3 0 , and 5 0 -GCA-CGA-GAC-TAG-TGA-GAC-GTG-3 0 . B6.129S4-Mbl1
tm1Kata
.Mbl2 tm1Kata /J mice (also acquired from The Jackson Laboratory) were backcrossed for 3 generations to B10.Q.Ncf1 m1J mice. The mice were genotyped for the MBL1 gene using the primers 5 0 -CTG-AAG-GGC-CAG-TTC-ATG-TAC-GTG-ACA-GGG-GGG-3 0 , 5 0 -CCA-GAG-AGG-AGG-CAA-GGA-GAA-TAT-GGA-GG-3 0 , and 5 0 -GAT-CTC-CTG-TCA-TCT-CAC-CTT-GCT-3 0 ; the MBL2 gene was genotyped using the primers 5
/J mice (stock no. 002216 The Jackson Laboratory) were backcrossed to B10Q.Ncf1 mice for 3 generations and genotyped according to the supplier's instructions.
All mice were housed in specific pathogen-free conditions in either open cages (25) Induction of CAIA. CAIA was induced in mice by injection of a cocktail of 4 monoclonal anti-CII antibodies, produced in-house from the clones U1, M2139, CIIC1, and CIIC2. Antibodies were injected intravenously (IV) according to a previously reported protocol (11) . The mice were subsequently injected with 2 mg of mannan (M7504, CAS no. 9036-88-8; Sigma) intraperitoneally (IP) on days 5 and 60 or with 25 lg of LPS (L2880; Sigma) IP on day 5. Disease development in the paws was followed up macroscopically with blinded scoring of each red and swollen joint. In this arthritis scoring system, 1 point was assigned for each swollen and red toe or knuckle, and 5 points were assigned for each inflamed ankle, for a total arthritis score of 60 possible points per mouse.
EndoS, which specifically hydrolyzes the b-1,4-di-Nacetylchitobiose core of the asparagine-linked glycan of IgG, was used to generate CAIA anti-CII antibodies that bind weakly to Fc receptors (FcRs), and that therefore are less able to activate complement through C1q. Pretreatment of anti-CII antibodies with EndoS was performed as previously described (27, 28) .
Enzyme-linked immunosorbent assay (ELISA). Serum anti-CII antibody levels were determined by ELISA, as previously described (23, 25) . Briefly, Nunc Maxisorp 96-well plates (ThermoFisher Scientific) were coated with rat pepsin-digested CII (8041006-B; BD Biosciences) and then blocked with bovine serum albumin (fraction V; Immuno Diagnostic Oy). Serum samples were diluted in phosphate buffered saline and incubated on the coated plates for 2 hours at room temperature. The levels of bound anti-CII antibodies were detected using biotinylated Ig, j light chain (clone 187.1; BD Biosciences), and streptavidin-conjugated Europium (PerkinElmer). A Victor 1420 multilabel counter (PerkinElmer) was used to measure time-resolved fluorescence. 1344 HAGERT ET AL Flow cytometry. Flow cytometry analyses of peripheral blood samples obtained from the mice were performed as described earlier (8, 25) . Briefly, red blood cells were lysed with hypotonic buffer, and then FcRs were blocked using rat IgG2b blocking of CD16/CD32 (553142; BD Biosciences) and surface antigens were stained with fluorescence-labeled antibodies. For intracellular staining, the cells were fixed and permeabilized with Cytofix/Cytoperm solution (554722; BD Biosciences) according to the manufacturer's protocol. The antibodies used were fluorescein isothiocyanate (FITC)-conjugated Ly-6G (551460), allophycocyanin (APC)-conjugated CD11c (550261), APC-conjugated B220 (561880), and FITC-conjugated CD3 (553062) (all from BD Biosciences), and Alexa Fluor 405-conjugated CD11b (51-4801; from eBioscience). The samples were collected on an LSRII flow cytometer (BD Biosciences) and analyzed using FlowJo software, version 10 (Tree Star).
Histology. At termination, the mouse paws were fixed in 4% paraformaldehyde, decalcified, and paraffin-embedded. Sections were cut at a thickness of 7 lm and stained with hematoxylin and eosin or Safranin O to assess general levels of inflammation. The slides were then scanned using a Pannoramic 250 Slide Scanner and analyzed using Pannoramic Viewer, version 1.15.4 (both from 3D Histech). Scoring of inflammation was performed as previously described (26) . Briefly, a score of 1 represents mild synovitis (some infiltration of inflammatory cells, with no bone or cartilage erosion), a score of 2 represents moderate synovitis (inflammation, some cartilage erosion, but undisrupted joint architecture), and a score of 3 represents a disrupted joint architecture with many infiltrating cells, severe pannus formation, and widespread erosion of both bone and cartilage.
Statistical analysis. Disease scores and results of cell expression analyses were compared by Mann-Whitney test. Figure 1 . Development of mannan-enhanced collagen antibody-induced arthritis (CAIA) is dependent on the presence of reactive oxygen species (ROS)-deficient macrophages. A, After injection (inj.) of anti-type II collagen (anti-CII) antibodies (ab) and subsequent immune stimulation with mannan on days 5 and 60, arthritis severity scores and prevalence of arthritis over time were assessed in ROS-deficient mice compared to MN and wild-type (WT) control mice. ROS-deficient mice had an m1J point mutation in the gene for neutrophil cytosolic factor 1 (Ncf1* / *), while MN and WT control mice expressed functional Ncf1, and therefore produced ROS only in monocytes/macrophages. B, Arthritis severity scores and prevalence of arthritis over time were investigated in Ncf1-deficient and WT control mice that were injected with mannan but not with anti-CII antibodies. Results in A and B are the combined data from 2 experiments in 8-11 mice per group. Values are the mean AE SEM. Arrowheads indicate administration of mannan on days 5 and 60. C, The histologic characteristics of mannan-enhanced CAIA were assessed. The representative images from an Ncf1-deficient mouse show swelling and redness of the paws on days 0, 2, 14, 67, and 152 after anti-CII antibody injection. Statistical analyses were performed by Mann-Whitney test. * = P < 0.05; ** = P < 0.01; *** = P < 0.001 for Ncf1-deficient versus WT control mice.
= P < 0.05;^^^= P < 0.001 for Ncf1-deficient versus MN control mice. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.40482/abstract. Data were analyzed using the GraphPad Prism program, version 5.
RESULTS
Macrophage-driven, ROS-dependent chronic disease in mice with mannan-enhanced CAIA. An IV injection of a cocktail of 4 monoclonal anti-CII antibodies and subsequent IP injections of mannan on days 5 and 60 induced chronic arthritis in B10.Q mice. The acute phase of the disease occurred between days 10 and 40 and peaked around day 20. The disease then progressed into a chronic phase that peaked on day 70, stabilized around day 80, and continued through day 151. This chronic disease was dependent on ROS deficiency, as it only developed in mice with a mutation in the Ncf1 gene (designated Ncf1*/* in Figure 1A) , which results in a defective NOX-2 complex (29) . MN mice, in which functional Ncf1 is reintroduced to Ncf1-deficient mice under the human CD68 promotor, and which therefore only produce ROS from the NOX-2 complex in monocytes/macrophages, did not develop CAIA ( Figure 1A ). Macrophages thus appear to be one of the major drivers of the disease in this model.
It was also noted that injection with mannan without prior exposure to anti-CII antibodies induced a mild disease in Ncf1-deficient mice ( Figure 1B) . However, both the severity and the prevalence of arthritis were significantly lower than that in mice exposed to both anti-CII antibodies and mannan ( Figures 1A and B) . The serum anti-CII levels in mice with mannan-enhanced CAIA decreased steadily during the acute phase of the disease and were undetectable by the onset of the chronic phase (see Supplementary Figure 1 , available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40482/abstract), independent of the disease severity or genotype of the mice. Ncf1-deficient mice (mice deficient in the gene for neutrophil cytosolic factor 1 [Ncf1*/*]) have more inflammation in the paws and higher levels of peripheral blood neutrophils compared to wild-type (WT) and MN control mice with chronic arthritis. A and B, Paws were collected from Ncf1-deficient mice with chronic disease and stained with hematoxylin and eosin (H&E) (A) or Safranin O (B) to assess levels of inflammation. Representative images of the front paws on day 76 are shown. Original magnification 9 20. C, H&E-stained paws were scored for cell infiltration and bone erosion on a scale of 0-3. Results are the combined data from 3 independent experiments in 8-13 mice per group. Values are the mean AE SEM. D, Paws were collected on days 76, 130, and 151. Results of flow cytometry analyses on day 147 show an increase in monocytes (Mono) (CD11b+Ly-6GÀ) and neutrophils (Neu) (CD11b+Ly-6G+) in the peripheral blood of Ncf1-deficient mice compared to control mice. Values are the mean AE SEM of the indicated number of mice per group. E, H&E-stained sections of the joints from a chronically ill Ncf1-deficient mouse on day 130 show cell infiltration, comprising primarily macrophages and neutrophils. Boxed area on the left is shown at higher magnification on the right (original magnification 9 10 on left; 9 60 on right). DC = dendritic cells (CD11c+). * = P < 0.05; ** = P < 0.01; *** = P < 0.001 by Mann-Whitney test.
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HAGERT ET AL Disease characteristics in mice with mannanenhanced CAIA. The symptoms of the disease induced by anti-CII antibodies and mannan consisted of swelling and redness of both the front and hind paws ( Figure 1C) . These symptoms were similar in the acute and chronic phases, with the only difference being possible deformation of the paws during the chronic phase. Occasional psoriatic lesions were also observed directly after the injection of mannan; however, these lesions did not become chronic (Hagert C, et al: unpublished observations). Therefore, it could be concluded that the psoriatic lesions were mannan-dependent, consistent with previous observations (26) , and were present with or without the addition of anti-CII antibodies.
Differences in the development of disease between the genotypes were also observed at the histologic level (Figures 2A and B) , since Ncf1-deficient mice had more prominent cellular infiltration in the paws and more erosion of bone and cartilage than did either wild-type or MN mice. These gross observations were confirmed with histologic scoring of inflammation ( Figure 2C ).
In addition, flow cytometry analysis of peripheral blood collected on day 147 showed an increase in the number of monocytes and neutrophils in Ncf1-deficient mice ( Figure 2D ). Infiltration of inflammatory cells, consisting primarily of neutrophils and macrophages, into the synovium of the paws on day 130 was also observed ( Figure 2E) .
The disease in the acute phase primes for the development of chronicity. It was observed that remission and relapse of arthritis occurred during the chronic phase of the disease in mice with mannan-enhanced CAIA (Figure 1A) . To investigate whether the chronic phase is dependent on the acute phase, the mean arthritis scores for each mouse in the acute phase were plotted against the mean arthritis scores in the chronic phase. The mice in which disease later progressed to the chronic phase all showed signs of arthritis in the acute phase. This result was observed regardless of whether the arthritis score per paw or the combined arthritis score from all the paws was used. Furthermore, because the severity of arthritis per paw in the remission phase and that in the relapse phase Figure 3 . Arthritis in the mannan-enhanced collagen antibody-induced arthritis (CAIA) model largely recurs in previously affected joints during the chronic phase of the disease. To show the fluctuations in arthritis during the course of the disease, inflammation in each joint from a mouse with mannan-enhanced CAIA was plotted on a heatmap (A), in which each paw was numbered according to the scheme shown in B. The data were also plotted graphically, illustrating changes in the numbers of affected joints over time and the number (C) and percentage (D) of new joints affected since day 101. All mice (n = 6) were littermates and were Ncf1-deficient.
were correlated, it appears that the same joints that had been affected during the acute phase often exhibited relapse during the chronic phase of the disease. An animation of the score changes in paws from a representative mouse from days 101-151 illustrates the development of the disease (see Supplementary Video 1, available on the Arthritis & Rheumatology web site at http://onlinelibrary. wiley.com/doi/10.1002/art.40482/abstract). In Figure 3A , the arthritis scores per joint in all mice are presented as heatmaps, based on the numbering of the joints shown in Figure 3B . Thus, these findings show that arthritis primarily recurred in previously affected joints, although new joints did occasionally develop arthritis during the chronic phase ( Figures 3C and D) .
Chronic disease development without dependence on T and B cells. Since, traditionally, CAIA represents a disease that is independent of T and B cells, we investigated whether the current novel model of CAIA also operates in a manner independent of T cells and B cells in the immune system. Studies in RAG-knockout mice on a B10.Q Ncf1-deficient background demonstrated that B cells, ab T cells, cd T cells, and natural killer T cells (30) do not drive either the acute or the chronic phase of mannan-enhanced CAIA (Figures 4A and B) . This was further confirmed using bTCR-knockout mice, an experimental model in which mice develop an arthritic disease similar to that in bTCR-sufficient littermates upon administration of anti-CII antibodies and mannan ( Figure 4C , and Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40482/abstract).
Chronic disease development without dependence on FccRIII. Antibodies can regulate immune responses and can trigger inflammatory cell activation through interactions with FcRs. FcRs are expressed on numerous immune cells, including macrophages and neutrophils, which are important effector cells in acute CAIA (31) (32) (33) . In mice injected with mannan without previous exposure to anti-CII antibodies, a milder disease was evident as compared to that in mice that had been previously exposed to anti-CII antibodies ( Figures 1C and  D and Figures 5B and D) , indicating that the injected anti-CII antibodies have an important role in promoting the severity of the disease. The CAIA cocktail consists of IgG2a and IgG2b antibodies (11) , which interact with the immune complex receptor FccRIII (31) . Thus, we tested the model in FccRIII-knockout mice. The results showed that the FccRIII receptor does not play an important role in the severity of the disease (Figure 5A) , nor does it affect the prevalence of the disease (Supplementary Figure 3A , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40482/abstract).
To further address the role of FcRs, the anti-CII antibodies were pretreated with EndoS. EndoS specifically hydrolyzes the N-linked glycan in the Fc region of native IgG, decreasing its binding affinity for FcRs, including FccRIII (27) . However, EndoS also affects the ability of antibodies to activate complement via the classical pathway (34) . Indeed, the EndoS-treated anti-CII antibodies caused a less severe disease than that seen with untreated anti-CII antibodies ( Figure 5B), both in the acute phase and in the chronic phase of the disease. In fact, in terms of both severity and prevalence (Supplementary Figure 3B , http:// onlinelibrary.wiley.com/doi/10.1002/art.40482/abstract), the disease induced with EndoS-treated antibodies resembled that induced with mannan only, indicating that the antibodies lost their ability to contribute to the development of mannan-enhanced CAIA. This effect was not specific to mannan-enhanced CAIA, as it was also present in LPSinduced CAIA (Supplementary Figure 4 , http://onlinelibrary. wiley.com/doi/10.1002/art.40482/abstract).
Role of the complement cascade as a driver of mannan-enhanced CAIA. The observation that the disease was not affected in FccRIII-knockout mice but was affected by disrupting FcR binding with EndoS suggests that complement-mediated mechanisms might be involved. Furthermore, the complement system has previously been shown to play a role in LPS-enhanced CAIA (24, 35) . We also observed neutrophil infiltration of the joints and an increase in neutrophil numbers in the peripheral blood during the chronic phase of mannan-enhanced CAIA (Figure 2) , further suggesting that complement is involved. CAIA was induced in Ncf1-deficient B10.Q mice with a mutation in the gene encoding complement factor C5 (a mutation leading to complete absence of C5), and C5-deficient mice developed a significantly milder disease than that in control mice, both with regard to the severity of arthritis ( Figure 5C ) and its prevalence (Supplementary Figure 3C Mannan-enhanced collagen antibody-induced arthritis (mCAIA) is dependent on complement, but not on the lectin pathway of complement activation or on Fcc receptor type III (FccRIII). Arthritis inflammation severity scores were compared between several groups of mice with mannan-enhanced CAIA or controls injected with mannan only or left untreated (naive). A, FccRIII-knockout Ncf1-deficient mice versus control Ncf1-deficient mice (results illustrative of 2 experiments in 4-5 mice per group). B, Ncf1-deficient mice injected with EndoS-treated anti-type II collagen (anti-CII) antibodies (EndoS) versus control Ncf1-deficient mice that received non-EndoS-treated anti-CII antibodies (Normal) (n = 10-13 in the mCAIA groups, n = 8-13 in the control groups). C, Complement factor C5-knockout Ncf1-deficient mice versus control Ncf1-deficient mice (n = 8-10 per group). D, Mannan-binding lectin 1 (MBL-1)/MBL-2-knockout Ncf1-deficient mice versus control Ncf1-deficient mice (n = 14-21 in the mCAIA groups, n = 5-10 in the control groups). Arrowheads indicate administration of mannan on days 5 and 60. Results are the mean AE SEM. Statistical analyses were performed by Mann-Whitney test. * = P < 0.05; ** = P < 0.01; *** = P < 0.001.
Since mannan can activate the complement cascade via mannan-binding lectin (MBL), this model was tested in mice deficient in both MBL-1 and MBL-2. However, there was no difference between the MBL-1/MBL-2-knockout mice and their heterozygous littermate controls with regard to disease severity ( Figure 5D ) or prevalence (Supplementary Figure 3D , http://onlinelibrary.wiley.com/doi/10.1002/ art.40482/abstract).
DISCUSSION
We developed a new model for studies of RA, a model of chronic active arthritis that is independent of T and B cells and driven only by innate immunity. RA is a chronic relapsing disease in which erosive arthritis occurs in multiple joints (1) . The driving forces of chronicity in RA are not known and can differ across various forms of the disease. The current dogma is that chronicity is autoimmune and T cell-dependent, based on the fact that RA is strongly associated with MHC class II genes and is characterized by the production of IgG autoantibodies. However, it is likely that both the genetic association and the possible pathogenic role of the autoantibodies are important mainly in the early phases of the disease (1, 36) . MHC class II seems to be more strongly associated with antibody levels than with the development of chronic disease. Consequently, during the chronic phase of the disease, treatments targeting adaptive immune mechanisms are less effective.
In animal models, the initial phases of the disease are dependent on MHC class II genes and a pathogenic immune response mediated by T cells (17) and, in some models, by B cells producing pathogenic antibodies. Many of these models, including the classic model of CIA, which is induced with heterologous CII, and LPS-enhanced CAIA, do, however, lack a chronic phase (11) (a comparison between acute CAIA and the current mannanenhanced chronic CAIA model is summarized in Table 1 ). In models induced with autologous proteins that trigger autoreactive T cells, a chronic active arthritis develops, and this is observed to be T cell-dependent (1, 18, 37) . It has also been shown that Tcells could regulate the chronic disease through, for example, enhancement of chronic arthritis by specific ablation of Treg cells (18) . The best evidence for a chronic disease model involving pathogenic MHC class II-restricted T cells could be PIA, in which the arthritis is driven by the T cells, without involvement of antibodies (38) . In contrast, some genetically modified models, such as mice overexpressing tumor necrosis factor (TNF), indeed develop an active chronic arthritis without the involvement of T cells. However, this is dependent on the aberrantly high levels of TNF produced in those mice (39) .
The observation that mannan could induce chronic arthritis in mice pretreated with anti-CII antibodies came as a surprise and seems to represent a novel mechanism through which innate immunity can drive chronic disease. The chronicity in this model is not likely to be attributable to persistently increased production of anti-CII antibodies, as the levels of anti-CII antibodies in the mice returned to baseline levels long before the onset of chronicity. Furthermore, antibodies binding the joint cartilage are unlikely to be driving the chronic disease, since the levels of these antibodies are in equilibrium with circulating antibodies (24, 40) . Moreover, if this was the case, the classic model of CAIA enhanced with LPS would be chronic, which is not the case (11) . Another possibility is that the injected mannan persists and triggers chronic activation of macrophages in the joints. However, the accumulation of mannan in the joints would have to be somehow exacerbated by the prior injection of anti-CII antibodies, since mannan alone does not have the same effects. Importantly, the chronic state of the disease persists, with additional relapses continuing to occur, for an extended time after the second injection of mannan, which makes the possibility of a continuous mannanmediated activation less likely. Even if persistent mannan exposure contributes to the development of chronicity, this could be physiologically relevant, as humans are also (32, 33) No role * CAIA = collagen antibody-induced arthritis; CII = type II collagen; LPS = lipopolysaccharide; LM = lipomannan; MPL = monophosphoryl lipid A; Ncf1 = gene for neutrophil cytosolic factor 1; ROS = reactive oxygen species; FccRIII = Fcc receptor type III.
exposed to mannan through the gastrointestinal tract (food, beer), lungs (air, infections), and skin (infections). Mannan most likely plays a role in this arthritis model by activating macrophages, probably via patternrecognition receptors such as Toll-like receptor 4 (TLR-4) and/or dectin-2 (41). In fact, TLRs, including TLR-2 and TLR-4, have been linked to the development of RA both in humans and in mice (1, 13, 42) . If innate immune cells, presumably macrophages in particular, enter a vicious circle of activation with or without mannan, it is clearly controlled by ROS, since a functional NCF-1/NOX-2 complex in macrophages suppresses the development of chronic arthritis, both in CIA (5) and in mannanenhanced CAIA. Importantly, susceptibility to human RA is associated with the NCF1 copy number and NCF-1 polymorphisms, although these play different roles in different autoimmune diseases, and the exact role of the ROS response has not yet been clarified (2, 3, 43, 44) .
In addition, we were unable to dissect the precise mechanism whereby activated macrophages drive chronic arthritis. Clearly, these mechanisms are not dependent on T cells or B cells. Antibody-mediated activation of macrophages is also not relevant, as mice deficient in the major FcR receptor that binds IgG2a and IgG2b, FccRIII, developed chronic disease. It should be observed that FccRI does bind these Ig, although as monomeric antibodies and not as immune complexes (31) . In addition, since the anti-CII antibodies were undetectable in the mouse serum in the chronic phase, it is unlikely that these will be involved in driving the disease. However, activation of the complement system is critical, although we do not yet know whether complement activation contributes only to disease initiation or whether it also drives the development of chronic disease. An attractive hypothesis was that mannan binds to MBL and thus activates the lectin complement pathway. Surprisingly, this was not the case, as the development of chronic disease was unaltered in MBL-deficient mice.
The complement system has previously been implicated in the development of RA (1), although it is believed to mainly operate in the acute inflammatory phase and not during chronic inflammation. Macrophages are obviously involved in the development of chronic RA, as they are always abundantly present in pannus tissue (45, 46) , whereas infiltrating lymphocytes are not always observed. Macrophages are also the main source of a number of inflammatory cytokines, including TNF, that are known to be important in RA pathogenesis. It will also be important to understand the interplay between macrophages and fibroblasts, particularly because fibroblasts are critical in the TNF-transgenic model of RA (47) . Another interesting cell type to address would be monocytic myeloid-derived suppressor cells (CD11b+Ly-6C+), which also have been found in RA patients and that possibly could be a source of ROS in this model (48) . In fact, we have previously shown an increase in the number of myeloid-derived suppressor cells in a recombinant Ncf1 mouse, which decreased after Ncf1 induction both in the early stages and in the later stages of arthritis (49) . It is well known that subtypes of macrophages express the macrophage mannose receptor, a receptor known to bind mannan. Since this macrophage subtype is down-regulating the immune system, the possibility that mannan activates these cells is intriguing, and this concept has recently been addressed (50) .
Taken together, these findings indicate that this novel model of mannan-enhanced CAIA could be useful for studies of the role of macrophages in RA, particularly as a driver of chronicity. Thus far, our data suggest that, for certain subtypes of RA, treatments targeting subtypes of chronically activated macrophages could potentially be of value.
